drugset / Trial / NCT03906695
Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To investigate the tolerability and safety of ASTX727 in Japanese subjects with lower-risk MDS.
Timeline
- Start
- 2019-03-15
- Primary completion
- 2026-01-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cedazuridine | Small molecule | — | Oral |
| Subject | Decitabine | Small molecule | 5 mg | Oral |
| Subject | Decitabine | Small molecule | 10 mg | Oral |
| Subject | Decitabine | Small molecule | 20 mg | Oral |